AbbVie Inc. (NYSE:ABBV) declared $1.73 per share quarterly dividend, this is a 5.5% increase from prior dividend of $1.64. Forward yield is 3.03%. Dividend is payable on February 17th for shareholders of record on January 16th. Ex-dividend date is January 16th.
Showing posts with label ABBV. Show all posts
Showing posts with label ABBV. Show all posts
Friday, October 31, 2025
Wednesday, October 30, 2024
Dividend increase #41 of 2024 : AbbVie Inc.
AbbVie (NYSE:ABBV) declares $1.64/share quarterly dividend, 5.8% increase from prior dividend of $1.55. Forward yield 3.46%. Dividend is payable on February 14th for shareholders of record on January 15th. Ex-dividend data is January 15th.
Monday, October 30, 2023
Dividend increase #40 of 2023 : AbbVie Inc.
AbbVie Inc. board declared an increase in the company's quarterly cash dividend from $1.48 per share to $1.55 per share beginning with the dividend
payable on February 15, 2024 to shareholders of record as of January
16, 2024. This reflects an increase of approximately 4.7 percent.
Monday, October 31, 2022
Monday, November 1, 2021
Dividend increase #35 of 2021 : AbbVie Inc.
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022.
This reflects an increase of approximately 8.5 percent, continuing
AbbVie's strong commitment to returning cash to shareholders through a
growing dividend. Since the company's inception in 2013, AbbVie has
increased its quarterly dividend by more than 250 percent. AbbVie is a
member of the S&P Dividend Aristocrats Index, which tracks companies
that have annually increased their dividend for at least 25 consecutive
years.
Since I own 42 shares of ABBV, this change will increase my 12 month forward dividends by $18.48
Tuesday, October 12, 2021
Thursday, July 15, 2021
Wednesday, April 7, 2021
Friday, October 30, 2020
AbbVie increases dividend
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.18 per share to $1.30 per share beginning with the dividend payable on February 16, 2021 to shareholders of record as of January 15, 2021 . This reflects an increase of approximately 10.2 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
Friday, July 10, 2020
Wednesday, January 8, 2020
Friday, November 1, 2019
AbbVie increases dividend
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.07 per share to $1.18 per share beginning with the dividend payable on February 14, 2020 to shareholders of record as of January 15, 2020. This reflects an increase of approximately 10.3 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 195 percent. AbbVie
is a member of the S&P Dividend Aristocrats Index, which tracks
companies that have annually increased their dividend for at least 25
consecutive years.Since I own 21 shares of ABBV, this change will increase my 12 month forward dividends by $9.24
Thursday, October 3, 2019
Monday, July 1, 2019
Tuesday, April 2, 2019
New purchase : Abbvie Inc.
New position started in the porfolio. Purchased 6 shares of Abbvie Inc (NYSE:ABBV) at $80.54 per share. Abbvie pays dividends with 2-5-8-11 schedule and my starting yield of cost is at 5.30%
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.
Subscribe to:
Posts (Atom)


